Quest Diagnostics Inc

NYSE: DGX
$137.55
+$0.85 (+0.6%)
Closing price April 24, 2024
Quest Diagnostics is a leading provider of diagnostic testing and services globally. With a focus on delivering comprehensive diagnostic information through routine, advanced clinical, and anatomic pathology testing, it serves a wide range of clients including physicians, hospitals, patients, health plans, and government agencies. Operating under the Quest Diagnostics brand and others like AmeriPath and ExamOne, it has a vast network of laboratories and patient service centers. Additionally, it offers risk assessment services for the life insurance industry and IT solutions for healthcare organizations. Founded in 1967, Quest is headquartered in Secaucus, New Jersey.
Thursday's top analyst upgrades and downgrades included Alphabet, BP, Chevron, DraftKings, Exxon Mobile, FedEx, NextEra Energy, Nikola, Penn National, Twitter and Zillow.
With solid total return potential, and seemingly far less potential for volatility, these five BofA Securities quality stock picks are all outstanding long-term portfolio additions.
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Amgen, DexCom, eBay, FireEye, Kraft Heinz, 3M, Pfizer, Seagate Technology, Sonos, Starbucks and T-Mobile.
The number of COVID-19 cases continues to rise, which will only create more demand for coronavirus stocks. 24/7 Wall Street has picked out a few of the best and brightest that could still see a big...
One of the most important aspects of reopening the economy during this pandemic is testing for COVID-19. Credit Suisse sees a couple of winners benefitting incredibly from this.
These are four top telehealth plays for growth investors that offer a way to not only catch the swelling trend but to have a health care position for portfolios that should remain strong for the rest...
Tuesday's top analyst upgrades and downgrades included Avaya, Biogen, Broadcom, Chevron, Domino's Pizza, eBay, MGIC Investment, RealReal, Sprout Social, T-Mobile, Zoom Video Communications and Zynga.
Investors look at Aytu BioScience as it looks at expanding in the COVID testing field.
Aytu BioScience has a distribution agreement for a COVID-19 rapid test and is developing a potential UV light-based treatment.
This specialty pharmaceutical company is making good progress on multiple fronts, including changes to its board of directors and with its test for and treatment of COVID-19.
Tuesday's top analyst upgrades and downgrades included AT&T, Cognex, Johnson & Johnson, Keurig Dr Pepper, PayPal, Roku, Shopify, Square, Valero Energy and Walt Disney.
Monday's top analyst upgrades and downgrades included Amazon.com, American Airlines, American Express, Beyond Meat, Caterpillar, Clorox, eBay, Gilead Sciences, Twitter, Verizon Communications and...
Aytu BioScience has been one of the biggest winners in the fight against the novel coronavirus. The company is sending 2,700 COVID-19 rapid tests to Denver for use with first responders.
Co-Diagnostics has been the toast of Wall Street after it went from penny stock status to a revered coronavirus testing stock.
Investors have begun trying to position themselves for the rest of 2020 in a post-bull market climate. One haven for investors throughout good times and hard times has been companies with safe and...